Aktiebolaget Segulah acquires shares in Senzime AB

Aktiebolaget Segulah has entered into an agreement to acquire 650,000 shares in Senzime AB.

Senzime develops unique medical devices that enable patients’ biochemical and physiological processes to be monitored before, during, and after surgery.

The company’s solutions aim to ensure maximum patient benefit, reduce surgical complications, and cut healthcare costs. Senzime operates in growing markets, with Europe and the US alone currently valued at over SEK 10 billion.

Following this transaction, the Segulah Group holds 3,150,000 shares in Senzime AB.

Senzime stock is listed on NASDAQ Stockholm First North

For additional information, please contact

Lennart Kalén, Vice-Chair Aktiebolaget Segulah, +46 70 536 26 00.